Whalegun
Home

Ultragenyx Pharmaceutical RARE paid Aviva Strategies $38K for lobbying in Q4 2025 · Health Issues

Trade details

Type
Lobbying report
Amount
$38,000
Quarter
Q4 2025
Stock
Ultragenyx Pharmaceutical RARE
Client
Ultragenyx Pharmaceutical
Reported
26/01/15

Up 0.0% from last quarter

What else happened in Ultragenyx Pharmaceutical around then

Filed or reported within 30 days of the trade day · 25/12/01~01/30

Ultragenyx Pharmaceutical's other lobbying reports